CCIA
SVA

Campbell & Co Investment Adviser’s Sinovac Biotech, Ltd SVA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-12,983
Closed -$66K – 358
2015
Q3 		$66K Buy
+12,983
New +$68.8K 0.04% 313

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Campbell & Co Investment Adviser's SVA Position: Q4 2015 in Review

Campbell & Co Investment Adviser sold out of Sinovac Biotech, Ltd (SVA) in Q4 2015, closing a stake of 12,983 shares — an estimated $66K sold.

Campbell & Co Investment Adviser first reported a position in SVA in Q3 2015 and held it in 1 quarter. The position peaked at $66K in Q3 2015. 40 funds tracked by Wall St. Rank hold SVA as of Q4 2015.

  • Campbell & Co Investment Adviser reported no remaining Sinovac Biotech, Ltd position as of Q4 2015 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 12,983 Sinovac Biotech, Ltd shares in Q4 2015, an estimated $66K.
  • Campbell & Co Investment Adviser first reported a position in Sinovac Biotech, Ltd in Q3 2015 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Sinovac Biotech, Ltd position peaked at $66K in Q3 2015.
  • 40 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q4 2015.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2015, filed 16 Feb 2016.